Co‐delivery of nucleoside‐modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA

@article{Verbeke2017CodeliveryON,
  title={Co‐delivery of nucleoside‐modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA},
  author={Rein Verbeke and Ine Lentacker and Laura Wayteck and Karine Breckpot and Mieke Rosalie Van Bockstal and Benedicte Descamps and Christian Vanhove and Stefaan C. De Smedt and Heleen Dewitte},
  journal={Journal of Controlled Release},
  year={2017},
  volume={266},
  pages={287–300}
}

Figures from this paper

Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy.

Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy

Recent advances in the development of lipid nanoparticles for mRNA-based immunotherapies and their applications in cancer treatment are summarized and the main factors affecting transfection efficiency and tropism of mRNA-loaded lipid nanoparticle in vivo are discussed.

Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant.

It is demonstrated in the present work that the co-delivery of mRNA and gardiquimod led to the effective antigen expression and DC maturation in vitro and the simultaneous delivery of the antigen and adjuvant both spatially and temporally via the core/shell nanoparticle carrier is found to be beneficial for tumor growth inhibition.

DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine.

  • Rui ZhangLin Tang Li Yang
  • Biology
    Journal of controlled release : official journal of the Controlled Release Society
  • 2020

In Vitro Transcribed mRNA Vaccines with Programmable Stimulation of Innate Immunity.

A strategy for increasing translation of a model IVT mRNA vaccine while simultaneously modulating its immune-stimulatory properties in a programmable fashion, without relying on delivery vehicle formulations is presented.

Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines

A diverse class of multifunctional immunoadjuvants in nucleic acid subunit vaccines are reviewed and a detailed description of their mechanisms of adjuvanticity and induction of specific immune responses are provided.

Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy

Nonviral nanodelivery systems of mRNA vaccines used for cancer gene therapy and immunotherapy and effectively delivering mRNA into cells and successfully activating the immune response are the keys to the clinical transformation of mRNA therapy.
...

References

SHOWING 1-10 OF 65 REFERENCES

Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.

The lipid nanoparticle formulation presented here is a promising vector for mRNA vaccine delivery, one that is capable of inducing a strong cytotoxic T cell response and further optimization, including the incorporation of different adjuvants, will likely enhance the potency of the vaccine.

Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.

It is demonstrated that mRNA lipoplexes induce a potent type I interferon response upon subcutaneous, intradermal and intranodal injection and blocking type I IFN signaling at the site of immunization through the use of an IFNAR blocking antibody greatly enhanced the prophylactic and therapeutic antitumor efficacy of mRNAlipoplexes in the highly aggressive B16 melanoma model.

Lipid-based mRNA vaccine delivery systems

This review reports lipid-based formulations (LBFs) that have proved preclinical efficacy and how smart intracellular delivery is achieved using pH-sensitive lipids or polymers for an efficient mRNA escape from endosomes and limitations regarding cytosolic mRNA location for translation.

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation

It is observed that RNA is rapidly and selectively uptaken by lymph node dendritic cells (DCs), implying that bioavailability of recombinant RNA vaccines in vivo highly depends on the density and the maturation stage of DCs at the administration site and are of importance for the design of RNA-based clinical immunotherapy protocols.

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

It is shown that DCs can be targeted precisely and effectively in vivo using intravenously administered RNA-lipoplexes (RNA-LPX) based on well-known lipid carriers by optimally adjusting net charge, without the need for functionalization of particles with molecular ligands.

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice

In a mouse model of a lethal congenital lung disease caused by a lack of surfactant protein B (SP-B), twice weekly local application of an aerosol of modified SP-B mRNA to the lung restored 71% of the wild-type SP- B expression, and treated mice survived until the predetermined end of the study after 28 days.

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

In tumor-bearing mice intralymphatic RNA vaccination elicited protective and therapeutic antitumor immune responses, resulting in a remarkable survival benefit as compared with other treatment regimens.

Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design

RNA sequence modification, delivery optimization, or concurrent use of appropriate compounds might be some of the strategies to finalize this aim to increase primary SAM expression and the resulting vaccine potency.

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon

Intravenous immunization of mice with LMPs containing ovalbumin, human papilloma virus E7, and tyrosinase-related protein-2 mRNA, either combined or separately, elicited strong antigen-specific T-cell responses and question the current notion that type I IFNs hamper particle-mediated mRNA vaccines.

Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.

...